title: Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.
abstract: BACKGROUND
  Cancer is associated with an increased risk of thromboembolic diseases, but data on the association between prostate cancer and thromboembolic diseases are scarce. We investigated the risk of thromboembolic disease in men with prostate cancer who were receiving endocrine treatment, curative treatment, or surveillance.
  
  
  METHODS
  We analysed data from PCBaSe Sweden, a database based on the National Prostate Cancer Register, which covers over 96% of prostate cancer cases in Sweden. Standardised incidence ratios (SIR) of deep-venous thrombosis (DVT), pulmonary embolism, and arterial embolism were calculated by comparing observed and expected (using the total Swedish male population) occurrences of thromboembolic disease, taking into account age, calendar-time, number of thromboembolic diseases, and time since previous thromboembolic disease.
  
  
  RESULTS
  Between Jan 1, 1997, and Dec 31, 2007, 30 642 men received primary endocrine therapy, 26 432 curative treatment, and 19 526 surveillance. 1881 developed a thromboembolic disease. For men on endocrine therapy, risks for DVT (SIR 2.48, 95% CI 2.25-2.73) and pulmonary embolism (1.95, 1.81-2.15) were increased, although this was not the case for arterial embolism (1.00, 0.82-1.20). Similar patterns were seen for men who received curative treatment (DVT: 1.73, 1.47-2.01; pulmonary embolism: 2.03, 1.79-2.30; arterial embolism: 0.95, 0.69-1.27) and men who were on surveillance (DVT: 1.27, 1.08-1.47; pulmonary embolism: 1.57, 1.38-1.78; arterial embolism: 1.08, 0.87-1.33). Increased risks for thromboembolic disease were maintained when patients were stratified by age and tumour stage.
  
  
  CONCLUSIONS
  All men with prostate cancer were at higher risk of thromboembolic diseases, with the highest risk for those on endocrine therapy. Our results indicate that prostate cancer itself, prostate cancer treatments, and selection mechanisms all contribute to increased risk of thromboembolic disease. Thromboembolic disease should be a concern when managing patients with prostate cancer.
  
  
  BACKGROUND
  Swedish Research Council, Stockholm Cancer Society, and Cancer Research UK.
authors.affiliation: King's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, UK. mieke.vanhemelrijck@kcl.ac.uk
authors.forename: Mieke
authors.initials: M
authors.lastname: Van Hemelrijck
authors.forename: Jan
authors.initials: J
authors.lastname: Adolfsson
authors.forename: Hans
authors.initials: H
authors.lastname: Garmo
authors.forename: Anna
authors.initials: A
authors.lastname: Bill-Axelson
authors.forename: Ola
authors.initials: O
authors.lastname: Bratt
authors.forename: Erik
authors.initials: E
authors.lastname: Ingelsson
authors.forename: Mats
authors.initials: M
authors.lastname: Lambe
authors.forename: Pär
authors.initials: P
authors.lastname: Stattin
authors.forename: Lars
authors.initials: L
authors.lastname: Holmberg
mesh_terms: D000368:Aged; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications* / Q000628:therapy; D012042:Registries; D012307:Risk Factors; D013548:Sweden; D013923:Thromboembolism / Q000453:epidemiology* / Q000209:etiology
references.citation: Urologe A. 2008 Mar;47(3):270-83
references.pmid: 18273599
references.citation: Stat Med. 1983 Apr-Jun;2(2):267-71
references.pmid: 6648141
references.citation: J Urol. 2008 Dec;180(6):2423-9; discussion 2429-30
references.pmid: 18930283
references.citation: Horm Metab Res. 2006 Apr;38(4):225-9
references.pmid: 16700002
references.citation: Am J Cardiovasc Drugs. 2005;5(3):141-54
references.pmid: 15901202
references.citation: Urology. 1998 May;51(5):775-80
references.pmid: 9610591
references.citation: Vasa. 2009 May;38(2):160-6
references.pmid: 19588304
references.citation: Asian J Androl. 2007 Nov;9(6):751-9
references.pmid: 17968460
references.citation: Urol Int. 2007;79(3):217-25
references.pmid: 17940353
references.citation: Int J Epidemiol. 2001 Oct;30 Suppl 1:S30-4
references.pmid: 11759848
references.citation: Scand J Soc Med. 1993 Mar;21(1):3-9
references.pmid: 8469941
references.citation: J Clin Endocrinol Metab. 2003 Dec;88(12):5723-9
references.pmid: 14671159
references.citation: Thromb Res. 2009;123 Suppl 4:S11-7
references.pmid: 19303496
references.citation: Eur Urol. 2007 Jan;51(1):130-5; discussion 136
references.pmid: 16942832
references.citation: Eur J Cancer. 2008 Mar;44(5):718-25
references.pmid: 18207733
references.citation: Semin Thromb Hemost. 2007 Feb;33(1):80-6
references.pmid: 17253194
references.citation: Maturitas. 1996 Jul;24(3):147-55
references.pmid: 8844628
references.citation: Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21
references.pmid: 12814981
references.citation: IARC Sci Publ. 1987;(82):1-406
references.pmid: 3329634
references.citation: Acta Oncol. 2009;48(1):27-33
references.pmid: 18767000
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):277-82
references.pmid: 10207628
references.citation: Eur J Heart Fail. 2005 Aug;7(5):787-91
references.pmid: 15916919
references.citation: Scand J Urol Nephrol. 2009;43(5):342-9
references.pmid: 19921977
references.citation: Lancet. 2008 May 17;371(9625):1710-21
references.pmid: 18486743
references.citation: Arch Intern Med. 2000 Mar 27;160(6):809-15
references.pmid: 10737280
references.citation: CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
references.pmid: 4625049
references.citation: Scand J Urol Nephrol. 2007;41(6):456-77
references.pmid: 17934985
references.citation: Eur J Endocrinol. 2005 Mar;152(3):479-83
references.pmid: 15757866
references.citation: Cancer. 2005 Apr 15;103(8):1615-24
references.pmid: 15742331
references.citation: Invest Urol. 1981 Mar;18(5):355-7
references.pmid: 7203959
references.citation: Eur Urol. 2008 Jan;53(1):134-45
references.pmid: 17597288
references.citation: Cancer. 2007 Oct 1;110(7):1493-500
references.pmid: 17657815
references.citation: Urologe A. 1994 Mar;33(2):172-4
references.pmid: 8178414
references.citation: Am J Epidemiol. 1998 Nov 15;148(10):1012-7
references.pmid: 9829874
references.citation: Thromb Res. 2007;121(1):127-34
references.pmid: 17451792
references.citation: BJU Int. 2007 Jun;99(6):1398-403
references.pmid: 17537215
references.citation: J Physiol Sci. 2008 Jun;58(3):173-7
references.pmid: 18445310
references.citation: Urol Res. 1981;9(1):25-8
references.pmid: 6455833